

## 文章

我的图书馆

时间不限

2015以来

2014以来

2011以来

自定义范围...

按相关性排序

按日期排序

搜索所有网页

中文网页

英语网页

☒ 包括专利☒ 包含引用☐ 创建快讯**Update: Clinically Significant Cytochrome P - 450 Drug Interactions**

EL Michalets - ... : The Journal of Human Pharmacology and Drug ..., 1998 - Wiley Online Library

... Reprinted by permission from Applied Pharmacokinetics: Principles of Therapeutic Drug

Monitoring, third edition ... in the inhibition of 3A4. 19 Data on significant drug interactions with these ...

60 mg t~ice/day, ~\* 56 Other studies reported similar pharmacokinetic changes but ...

被引用次数: 637 相关文章 所有 9 个版本 引用 保存

**Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update**

M Schachter - Fundamental &amp; clinical pharmacology, 2005 - Wiley Online Library

... Pravastatin is eliminated by both the kidney and liver, mostly as unchanged drug [33,57]. However,

as with some of the other currently available statins, its pharmacokinetics are altered in ... unchanged,

by both the kidney and liver [37,58], and its pharmacokinetic properties are ...

被引用次数: 457 相关文章 所有 4 个版本 引用 保存

**[HTML] Macrolide-induced clinically relevant drug interactions with cytochrome P - 450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and ...**

JF Westphal - British journal of clinical pharmacology, 2000 - Wiley Online Library

... The effect of dirithromycin on the steady-state pharmacokinetics of cyclosporin was ... wide margin

of safety associated with loratadine, the observed pharmacokinetic interaction is probably ... A

knowledge of drug interactions, for example those induced by macrolides, contributes to ...

被引用次数: 133 相关文章 所有 5 个版本 引用 保存

**[HTML] An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases**

MG Ghany, DR Nelson, DB Strader, DL Thomas... - ..., 2011 - Wiley Online Library

... has been approved by the American Association for the Study of Liver Diseases (AASLD) and ...

The Stevens Johnson Syndrome or Drug-Related Eruption with Systemic Symptoms (DRESS)

occurred ... of subjects but at a higher frequency than generally observed for other drugs. ...

被引用次数: 952 相关文章 所有 88 个版本 引用 保存

**Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition**

GK Dresser, JD Spence, DG Bailey - Clinical pharmacokinetics, 2000 - Springer

... A pharmacokinetic interaction study with lorazepam. ... The effects of the systemic antimycotics,

itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of

intravenous and oral midazolam. ... Ther Drug Monit 1986; 8: 305-17. ....

被引用次数: 779 相关文章 所有 6 个版本 引用 保存

dextroverse.org 中的 [PDF]

wiley.com 中的 [HTML]

wiley.com 中的 [HTML]

**Name of Journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO:** 20229

**Manuscript Type:** TOPIC HIGHLIGHT

**2015 Advances in Cirrhosis**

**Pharmacokinetic drug interactions in liver disease: An update**

Palatini P *et al.* Drug interactions in liver disease

Pietro Palatini, Sara De Martin

**Pietro Palatini, Sara De Martin**, Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35131 Padova, Italy

**Author contributions:** Palatini P and De Martin S analyzed the literature and wrote the manuscript.

## Match Overview

1	<b>CrossCheck</b> 364 words Pietro Palatini. "Enzyme Inhibition and Induction in Liver Disease", <i>Current Clinical Pharmacology</i> , 01/01/2008	2%
2	<b>Internet</b> 99 words crawled on 18-Jul-2015 <a href="http://www.wjgnet.com">www.wjgnet.com</a>	1%
3	<b>CrossCheck</b> 78 words De Martin, S., D. Gabbia, G. Albertin, M. M. Sfriso, C. Mescoli, L. Albertoni, G. Palluri, S. Bova, and P. Palatini. "Different	<1%
4	<b>CrossCheck</b> 32 words Florenzi, Maura, Sara De Martin, Daniela Gabbia, Massimo Barbierato, Alberto Nassi, Claudia Mescoli, Rocco Orlando,	<1%
5	<b>CrossCheck</b> 23 words "Irreversible CYP3A Inhibition Accompanied by Plasma Protein-Binding Displacement: A Comparative Analysis in Si ...	<1%
6	<b>CrossCheck</b> 22 words Howden, C.W. "Drug metabolism in liver disease", <i>Pharmacology and Therapeutics</i> , 1989	<1%



学术搜索 找到约 48,400 条结果 (用时0.04秒)

文章  
我的图书馆

时间不限  
2015以来  
2014以来  
2011以来  
自定义范围...

按相关性排序  
按日期排序

搜索所有网页  
中文网页  
简体中文网页

☒ 包括专利  
☒ 包含引用

☒ 创建快讯

小提示: 只搜索中文(简体)结果, 可在 学术搜索设置 指定搜索语言

**Update: clinically significant cytochrome P - 450 drug interactions**  
EL Michalets - ... : The Journal of Human Pharmacology and Drug ..., 1998 - Wiley Online Library  
... Reprinted by permission from Applied Pharmacokinetics: Principles of Therapeutic Drug  
Monitoring, third edition ... in the inhibition of 3A4.19 Data on significant drug interactions with these ...  
60 mg t~ice/day.~~\* 56 Other studies reported similar pharmacokinetic changes but ...  
被引用次数: 638 相关文章 所有 6 个版本 引用 保存

dextroverse.org 中的 [PDF]

**Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update**  
M Schachter - Fundamental & clinical pharmacology, 2005 - Wiley Online Library  
... Pravastatin is eliminated by both the kidney and liver, mostly as unchanged drug [33,57]. However,  
as with some of the other currently available statins, its pharmacokinetics are altered in ... unchanged,  
by both the kidney and liver [37,58], and its pharmacokinetic properties are ...  
被引用次数: 497 相关文章 所有 5 个版本 引用 保存

**Macrolide-induced clinically relevant drug interactions with cytochrome P - 450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin**  
JF Westphal - British journal of clinical pharmacology, 2000 - Wiley Online Library  
... The effect of dirithromycin on the steady-state pharmacokinetics of cyclosporin was ... wide margin  
of safety associated with loratadine, the observed pharmacokinetic interaction is probably ... A  
knowledge of drug interactions, for example those induced by macrolides, contributes to ...  
被引用次数: 134 相关文章 所有 5 个版本 引用 保存

wiley.com 中的 [HTML]

**[HTML] An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases**  
MG Ghany, DR Nelson, DB Strader, DL Thomas... - ..., 2011 - Wiley Online Library  
... has been approved by the American Association for the Study of Liver Diseases (AASLD) and ...  
The Stevens Johnson Syndrome or Drug-Related Eruption with Systemic Symptoms (DRESS)  
occurred ... of subjects but at a higher frequency than generally observed for other drugs. ...  
被引用次数: 1019 相关文章 所有 82 个版本 引用 保存

wiley.com 中的 [HTML]

**Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition**  
GK Dresser, JD Spence, DG Bailey - Clinical pharmacokinetics, 2000 - Springer  
The effects of the systemic antimycotics,

找到约 1,630,000 条结果 (用时 0.53 秒)

## Google 学术 : Pharmacokinetic drug interactions in liver disease: An update

... significant cytochrome P-450 drug interactions - Michalets - 被引用次数 : 640

... , pharmacokinetic and pharmacodynamic properties of ... - Schachter - 被引用次数 : 502

Macrolide-induced clinically relevant drug interactions ... - Westphal - 被引用次数 : 134

### Clinical pharmacokinetic and pharmacodynamic ...

[www.ncbi.nlm.nih.gov/pubmed/8582120](http://www.ncbi.nlm.nih.gov/pubmed/8582120) ▾ 翻译此页

作者 : DJ Morgan - 1995 - 被引用次数 : 157 - 相关文章

An update. ... The effects of liver disease on pharmacokinetics and pharmacodynamics are highly variable, ... account for the effects of chronic liver disease with cirrhosis on hepatic drug elimination: the ... However, if cirrhosis is present, 'safe' drug use requires an awareness of the possibility of multiple interactions between ...

### Clinical pharmacokinetics in heart failure. An updated review.

[www.ncbi.nlm.nih.gov/pubmed/3064953](http://www.ncbi.nlm.nih.gov/pubmed/3064953) ▾ 翻译此页

作者 : FV Shammas - 1988 - 被引用次数 : 91 - 相关文章

Pharmacokinetics is the study of the effect that the body has on drug absorption, ... to various organs including the sites of drug clearance, i.e. the liver and kidneys. ... in pharmacokinetics; rather, some may be due to important drug interactions.

### Effects of liver disease on pharmacokinetics. An update.

[www.ncbi.nlm.nih.gov/pubmed/10589374](http://www.ncbi.nlm.nih.gov/pubmed/10589374) ▾ 翻译此页